Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04422743
Other study ID # NP2017
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date January 25, 2018
Est. completion date September 11, 2020

Study information

Verified date November 2021
Source IRCCS Policlinico S. Matteo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

the general purpose of the study is to evaluate the potential beneficial effects of supplementation of a fixed combination of Citicoline 500 mg plus Homotaurine 50 mg on retinal ganglion cells (RGCs) function in subjects with glaucoma by pattern electroretinogram.


Description:

Secondary objectives are to assess effects on visual acuity, visual field changes, Quality of Life perception (NEI VFQ25 questionnaire), and safety (Incidence of adverse events)


Recruitment information / eligibility

Status Terminated
Enrollment 63
Est. completion date September 11, 2020
Est. primary completion date September 11, 2020
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - age between 40 and 75 years; - diagnosis of primary OAG (POAG) from, at least, 3 years; - visual acuity > 0.7 (7/10) decimals; - refractive error < 5 D (spheric) and < 2D (toric); - transparent diopter means (cornea and lens); - controlled IOP (<18 mmHg, morning value) with beta-blockers and prostaglandin analogues as monotherapy or as associative therapy (fixed or unfixed); - stable IOP<18 mmHg in the last 2 years; - stable and unchanged topical therapy in the last 6 months; - stable disease in the last 2 years (no more than -1 dB/year at MD of visual field); - at least two reliable visual fields (Humphrey 24-2 Swedish interactive threshold algorithm -SITA- Standard) per year in the last 2 years; - early to moderate visual field defect (MD <12 dB); - electrophysiological (PERG) parameters alterations similar to glaucomatous pathology; - written consent to participate to study procedures and data utilization in an anonymous form Exclusion Criteria: - ocular hypertension with normal optic nerve and visual field; angle closure glaucoma; - congenital glaucoma; secondary glaucoma; normal tension glaucoma; - history of recurrent uveitis/scleritis/herpes infection; - pregnancy and breastfeeding; - contraindication to Citicoline and/or Homotaurine - contraindication to beta-blockers and prostaglandine analogues - topical therapy with Brimonidine monotherapy or fixed combination (with timolol or brinzolamide) - topical therapy with pilocarpine and aceclidine, monotherapy or fixed combination systemic or topical treatment with another neuroprotective agent in the last 4 months prior to enrollment - systemic therapies affecting patients' performance in visual field examination (sedatives); - glaucomatous scotomas within 10 degree from fixation - any condition limiting the patient's ability to participate in the study; - other ocular causes of visual field and PERG changes, such as cataract, myopic chorioretinopathy, macular diseases, retinal vascular occlusion, diabetic retinopathy; - other systemic causes of visual field and PERG changes such as neurodegenerative disorders (Alzheimer's disease, Parkinson's disease, ALS, MS) or pituitary disorders; - cerebral ischemia in the last 2 years - any change in topical therapy in the 6 months prior to enrollment or during the study period concomitant participation to another clinical trial - any previous filtering and/or retinal surgery; - cataract surgery in the last 6 months; - any previous laser treatment for glaucoma in the last 5 years

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Citicoline 500 mg plus Homotaurine 50 mg
Citicoline 500 mg plus Homotaurine 50 mg was added to topical therapy

Locations

Country Name City State
Italy Dario Sisto Bari
Italy Alberto Mavilio Brindisi
Italy Gemma Caterina Maria Rossi Pavia PV
Italy Teresa Rolle Torino

Sponsors (1)

Lead Sponsor Collaborator
IRCCS Policlinico S. Matteo

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess effects of adding the fixed combination of Citicoline 500 mg plus Homotaurine 50 mg (Neuprozin® - NP), one tablet a day, on PERG examination at four months of therapy, compared to standard of care alone, as add-on to standard therapy changes in amplitude (microVolt) 4 months of therapy 2 months of wash out 4 months without adding therapy
Secondary To assess effects of one tablet a day of the fixed combination of Citicoline 500 mg plus Homotaurine 50 mg (Neuprozin® - NP) on visual acuity changes in visual acuity (decimals) 4 months of therapy 2 months of wash out 4 months without adding therapy
Secondary to assess effects of one tablet a day of the fixed combination of Citicoline 500 mg plus Homotaurine 50 mg (Neuprozin® - NP) on visual field changes in mean deviation (deciBell-dB) and in pattern standard deviation (deciBell-dB) of visual field parameters 4 months of therapy 2 months of wash out 4 months without adding therapy
Secondary to assess effects of one tablet a day of the fixed combination of Citicoline 500 mg plus Homotaurine 50 mg (Neuprozin® - NP) on quality of life changes in the total mean score and in the subscales of the 25 item National Eye Institute - Visual Functioning Questionnaire (NEI VFQ25) (scores are presented as a number, higher numbers reflect higher QL) 4 months of therapy 2 months of wash out 4 months without adding therapy
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A